Published in Anti-Infectives Week, September 20th, 2004
"Seventeen patients with early-stage chronic HIV type 1 infection were treated with highly active antiretroviral therapy (HAART) for 12 months. They were then randomized (day 0) to receive MMF (HAART-MMF group, n=9) or to continue the regimen (HAART group, n=6) for 120 additional days.
"At day 120 in the HAART-MMF group, HAART was discontinued, and MMF administration was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Anti-Infectives Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.